Puma Biotechnology Stock Crosses 200-Day Moving Average

Shares of the biopharmaceutical company reached a new high as analysts weigh in on its performance.

Mar. 17, 2026 at 7:33am

Got story updates? Submit your updates here. ›

Puma Biotechnology, Inc. (NASDAQ:PBYI) saw its stock price cross above its 200-day moving average on Monday, reaching as high as $6.13 per share. The biopharmaceutical company, which focuses on developing targeted cancer therapies, has seen its stock price fluctuate in recent months but is now trading at its highest level since early January.

Why it matters

Crossing above the 200-day moving average is often seen as a bullish technical indicator, suggesting the stock may be entering a period of sustained upward momentum. Puma Biotechnology's performance is being closely watched by investors and analysts as the company works to commercialize its lead drug, neratinib, for the treatment of early-stage HER2-positive breast cancer.

The details

Puma Biotechnology shares last traded at $6.07, with a volume of 227,113 shares traded. The stock has a 50-day moving average of $6.53 and a 200-day moving average of $5.67. The company has a market capitalization of $308.84 million and a price-to-earnings ratio of 9.95.

  • Puma Biotechnology's stock price crossed above its 200-day moving average on Monday, March 17, 2026.

The players

Puma Biotechnology, Inc.

A late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for oncology patients. The company's lead product is neratinib, which received FDA approval in 2017 for the extended adjuvant treatment of early-stage HER2-positive breast cancer.

Got photos? Submit your photos here. ›

The takeaway

Puma Biotechnology's stock price crossing above its 200-day moving average is a positive technical indicator for the company, which is working to commercialize its lead drug for the treatment of early-stage HER2-positive breast cancer. Investors and analysts will continue to closely monitor the company's performance as it navigates the competitive oncology market.